FDA 483 - Colgate-Palmolive Company - May 30, 2019

The FDA inspected Colgate Palmolive Company's Corporate Headquarters in Piscataway, NJ, and issued a Form 483 with one observation. The firm failed to submit copies of product labels with serious adverse event reports for OTC Monograph non-prescription drugs. This indicates a deficiency in their adverse event reporting process.